Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3).
about
Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular CarcinomaThe Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia TherapySuccessive phosphorylation of p27(KIP1) protein at serine-10 and C terminus crucially controls its potency to inactivate Cdk2TPL2 kinase regulates the inflammatory milieu of the myeloma nicheAnti-cancer natural products isolated from chinese medicinal herbs1,25-Dihydroxyvitamin D3 induces monocytic differentiation of human myeloid leukemia cells by regulating C/EBPβ expression through MEF2CERK5 pathway regulates transcription factors important for monocytic differentiation of human myeloid leukemia cells.The MAPK ERK5, but not ERK1/2, inhibits the progression of monocytic phenotype to the functioning macrophage.Dual role of hematopoietic progenitor kinase 1 (HPK1) as a positive regulator of 1α,25-dihydroxyvitamin D-induced differentiation and cell cycle arrest of AML cells and as a mediator of vitamin D resistanceAberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation.CUL4B promotes replication licensing by up-regulating the CDK2-CDC6 cascade.ERK 5/MAPK pathway has a major role in 1α,25-(OH)2 vitamin D3-induced terminal differentiation of myeloid leukemia cells.Role of cell cycle regulatory molecules in retinoic acid- and vitamin D3-induced differentiation of acute myeloid leukaemia cells.Vitamin D Control of Hematopoietic Cell Differentiation and Leukemia.Vitamin D has wide regulatory effects on histone demethylase genes.Activator of G-protein Signaling 3 Controls Renal Epithelial Cell Survival and ERK5 Activation.Established Human Cell Lines as Models to Study Anti-leukemic Effects of Flavonoids.Cell-Type-Specific Effects of Silibinin on Vitamin D-Induced Differentiation of Acute Myeloid Leukemia Cells Are Associated with Differential Modulation of RXRα Levels.TIMELESS Suppresses the Accumulation of Aberrant CDC45·MCM2-7·GINS Replicative Helicase Complexes on Human Chromatin.Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease.Silibinin: an old drug for hematological disorders.Optimal AraC-Cytotoxicity to AML Cells Requires ERK5 Activity.Nuclear ERK5 inhibits progression of leukemic monocytes to macrophages by regulating the transcription factor PU.1 and heat shock protein HSP70.
P2860
Q26767372-58AFC3EC-B751-4850-B56A-150DD45FE28BQ26799596-F288E0A4-2A29-40F3-AFEE-4D9E2C17D2E9Q28565092-84EDDE72-6C7B-4C54-B145-4EEB905C3CDFQ33714724-9F65E31D-A4F2-4243-A191-ACEFF2C503CCQ35143916-1FFC5597-CAC2-4108-B079-D85F3D780F91Q35181504-11146AE4-15AD-425A-9278-514101920584Q35189239-784BA43E-CEA5-420B-9F8F-9FC1B0E03C0DQ35189282-19AC2351-1BAF-43D0-B786-7440F4F2BD95Q35954885-0017021F-E2DF-4710-936D-FCEFABFBCA8DQ36293295-20A69271-CB47-4A65-9D2E-4CC059BC2BE1Q36695607-400E30E2-4123-4147-B64D-BAE58A7F64ABQ37724276-043CCBC2-585B-4035-A488-7E0C6E1FBB53Q38197273-4DF35AC3-F4FE-4D21-8853-AAF426F1BD60Q39037456-B51154A7-7FBD-4971-9EE4-1D2A124CC064Q39389302-1DEEC948-D459-45E4-9EFF-72BB83BA75F3Q40159153-6C1638CD-5B84-406E-A397-E20A4C2E0D65Q42320319-9ED604A4-1D2E-4280-9FFA-06AD2A06225EQ42352119-B8D3BC65-DC18-4F67-AAD4-12528C4F3E33Q42380615-3563FB68-3AC6-46DB-A937-E9DED9013F91Q42598206-F6C4A529-DE16-4EF0-A85A-9D49B27350ADQ42979759-83844AB7-07D0-4D3B-9E42-9E82C910586FQ45747315-270B333D-39E3-4699-95ED-D84378A08B78Q51283531-2F257F19-93FD-406D-BB6D-F7AD61F6C3A5Q51387239-528A2B61-FA2A-43CE-BA3C-077456B04E59
P2860
Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3).
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Inhibition of Cot1/Tlp2 oncoge ...... nd 1,25-dihydroxyvitamin D(3).
@ast
Inhibition of Cot1/Tlp2 oncoge ...... nd 1,25-dihydroxyvitamin D(3).
@en
Inhibition of Cot1/Tlp2 oncoge ...... nd 1,25-dihydroxyvitamin D(3).
@nl
type
label
Inhibition of Cot1/Tlp2 oncoge ...... nd 1,25-dihydroxyvitamin D(3).
@ast
Inhibition of Cot1/Tlp2 oncoge ...... nd 1,25-dihydroxyvitamin D(3).
@en
Inhibition of Cot1/Tlp2 oncoge ...... nd 1,25-dihydroxyvitamin D(3).
@nl
prefLabel
Inhibition of Cot1/Tlp2 oncoge ...... nd 1,25-dihydroxyvitamin D(3).
@ast
Inhibition of Cot1/Tlp2 oncoge ...... nd 1,25-dihydroxyvitamin D(3).
@en
Inhibition of Cot1/Tlp2 oncoge ...... nd 1,25-dihydroxyvitamin D(3).
@nl
P2093
P2860
P50
P356
P1433
P1476
Inhibition of Cot1/Tlp2 oncoge ...... and 1,25-dihydroxyvitamin D(3)
@en
P2093
George P Studzinski
Victoria Novik
Xuening Wang
P2860
P304
P356
10.4161/CC.9.22.13790
P577
2010-11-15T00:00:00Z